Status:
UNKNOWN
Immune Markers in Pediatric ITP on Second Line Therapy
Lead Sponsor:
Assiut University
Conditions:
ITP - Immune Thrombocytopenia
Eligibility:
All Genders
Up to 17 years
Brief Summary
Immune thrombocytopenia (ITP) is a common autoimmune disease characterized by low platelet count and increased risk of bleeding. It affects approximately 50 to 100 cases per million people per year, w...
Detailed Description
Antiplatelet factors in the plasma of ITP patients, specifically IgG, have been attributed to platelet destruction through phagocytosis or complement-mediated lysis. However, these antibodies are only...
Eligibility Criteria
Inclusion
- Pediatric patients diagnosed with immune thrombocytopenia who are undergoing second line therapy with either eltrombopag or romiplostim.
Exclusion
- Include acute immune thrombocytopenic children receiving first line therapy and those with secondary immune thrombocytopenia.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06093529
Start Date
January 1 2024
End Date
February 1 2025
Last Update
November 14 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.